ArticleCell death and differentiation2019
mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis.
Article in Cell death and differentiation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Overcoming Radiation Resistance: Ferroptosis Induction to Sensitize Solid Tumors to Radiation Therapy.Cancer medicine · 2026Review
- Inhibition of EphA2 triggers ferroptosis by disrupting USP38mediated SLC7A11 stabilization in chemoresistant gastric cancer.Cellular and molecular life sciences : CMLS · 2026Article
- Biological Roles of Melanin and Natural Product-Derived Approaches for Its Modulation.International journal of molecular sciences · 2026Review
- Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment.Cell death & disease · 2025Article
- System Xc-pathway as a potential regulatory target in neurological disorders.Frontiers in pharmacology · 2025Review
- The role of reactive oxygen species in gastric cancer.Cancer biology & medicine · 2024Review
- The metabolism of melanin synthesis-From melanocytes to melanoma.Pigment cell & melanoma research · 2024Review
- Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.Journal of experimental & clinical cancer research : CR · 2024Article
- Establishment of SLC7A11-knockout mouse and its preliminary investigation in melanoma.In vitro cellular & developmental biology. Animal · 2023Article
- Multi-omics data integration reveals the molecular network of dysregulation IQGAP2-mTOR promotes cell proliferation.Human cell · 2023Article
- AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells.Cell reports · 2023Article
- Maltol inhibits oxygen glucose deprivation‑induced chromatinolysis in SH‑SY5Y cells by maintaining pyruvate level.Molecular medicine reports · 2023Article
- eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest.International journal of molecular sciences · 2022Article
- Mechanism of HBV-positive liver cancer cell exosomal miR-142-3p by inducing ferroptosis of M1 macrophages to promote liver cancer progression.Translational cancer research · 2022Article
- Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells.Cancer cell international · 2021Review
- Modulating skin colour: role of the thioredoxin and glutathione systems in regulating melanogenesis.Bioscience reports · 2021Review
- Article
- Rapamycin Promotes ROS-Mediated Cell DeathFrontiers in oncology · 2021Article
- Identification of a Potentially Functional circRNA-miRNA-mRNA Regulatory Network in Melanocytes for Investigating Pathogenesis of Vitiligo.Frontiers in genetics · 2021Article
- Amino Acid Transporters Are a Vital Focal Point in the Control of mTORC1 Signaling and Cancer.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss of either TSC1 or TSC2 causes tuberous sclerosis complex (TSC) via activation of mTOR signaling pathway. The two prominent features of TSC are skin lesions including hypomelanic macules and benign tumors in multiple organs, whose molecular alterations are largely unknown. We report here that X
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.